Abstract
Inactivated vaccine BBIBP-CorV (Sinopharm; 95% (95%CI: 94%,97%)) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech; 98% (95%CI: 86%,99%)) demonstrated protection against COVID-19 related hospitalizations from the Delta (B.1.617.2) variant. Ongoing efforts are necessary to target vaccine hesitancy and promote booster shots for protection against severe COVID-19 disease and arising variants of concern.
Keywords: B.1.617.2; BBIBP-CorV; BNT162b2; COVID-19; Delta; SARS-CoV-2; vaccine effectiveness.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Delta, B.1.617.2, BNT162b2, BBIBP-CorV, vaccine effectiveness., 【초록키워드】 Vaccine, Hospitalization, mRNA vaccine, variant, variants of concern, Vaccine hesitancy, Effectiveness, severe COVID-19 disease, booster, effort, arising, demonstrated, promote, 【제목키워드】 Hospitalization, mRNA vaccine, Inactivated vaccine, outbreak, Effectiveness, Pfizer-BioNTech, Sinopharm,
【저자키워드】 COVID-19, SARS-CoV-2, Delta, B.1.617.2, BNT162b2, BBIBP-CorV, vaccine effectiveness., 【초록키워드】 Vaccine, Hospitalization, mRNA vaccine, variant, variants of concern, Vaccine hesitancy, Effectiveness, severe COVID-19 disease, booster, effort, arising, demonstrated, promote, 【제목키워드】 Hospitalization, mRNA vaccine, Inactivated vaccine, outbreak, Effectiveness, Pfizer-BioNTech, Sinopharm,